Hep Email Update UT Health Awarded Grants for MASLD Research Latinos make up a majority of San Antonians and are disproportionately impacted by MASLD, formerly known as fatty liver disease. Elafibranor Wins Accelerated Approval for Primary Biliary Cholangitis A second PPAR agonist, seladelpar, has also done well in clinical trials and is under FDA review. Biden Administration Advances Plan To Remove Medical Debt From Credit Scores If enacted, the rules would dramatically expand protections for tens of millions of Americans burdened by medical bills they can’t afford. Advertisement What Is Fatty Liver Disease? (MASLD and MASH) Learn the latest about fatty liver. What Is Hepatitis C? Get the basics! Hepatitis C Survey Tell us about your experience with hepatitis C. Advertisement Science News Elafibranor Wins Accelerated Approval for Primary Biliary Cholangitis Bulevirtide Plus Pegylated Interferon Can Maintain Undetectable Hepatitis D Revolutionary Advances in Liver Disease Research Unveiled at EASL Congress 2024 Armored CAR-T Therapy Shows Promise for Liver Cancer Newsfeed UT Health Awarded Grants for MASLD Research EASL Congress 2024: Combating Liver Disease Collectively CDC Confirms Second Human H5 Bird Flu Case in Michigan New Liver Transplant Policy Raises Concerns About Increased Costs and Equity Science News Elafibranor Wins Accelerated Approval for Primary Biliary Cholangitis Bulevirtide Plus Pegylated Interferon Can Maintain Undetectable Hepatitis D Revolutionary Advances in Liver Disease Research Unveiled at EASL Congress 2024 Armored CAR-T Therapy Shows Promise for Liver Cancer Newsfeed UT Health Awarded Grants for MASLD Research EASL Congress 2024: Combating Liver Disease Collectively CDC Confirms Second Human H5 Bird Flu Case in Michigan New Liver Transplant Policy Raises Concerns About Increased Costs and Equity

You are receiving this email because you opted in at one of our websites. At your request, this message was sent to newsletter@newslettercollector.com by update@hepmag.com. Please remember to add update@hepmag.com to your email address book, so that these updates aren't blocked as spam.

To change your subscription information and preferences, please visit your personal preferences page. Or you can unsubscribe completely from this list.

To forward this message, please do not use the forward button of your email application, because this message was made specifically for you only. Instead use the forward page in our newsletter system.

Did you receive this email from a friend? You can subscribe and you will receive our next newsletter directly to your inbox.

Our mailing address is: